

# JesÃ³s Barrio

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/999085/publications.pdf>

Version: 2024-02-01

71  
papers

2,928  
citations

147726

31  
h-index

175177

52  
g-index

73  
all docs

73  
docs citations

73  
times ranked

3250  
citing authors

#	ARTICLE	IF	CITATIONS
1	Room for Improvement in the Treatment of Helicobacter pylori Infection. Journal of Clinical Gastroenterology, 2022, 56, e98-e108.	1.1	36
2	Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry. Journal of Clinical Medicine, 2022, 11, 421.	1.0	8
3	Self-expandable metal stents versus endoscopic balloon dilation for the treatment of strictures in Crohn's disease (ProtDilat study): an open-label, multicentre, randomised trial. The Lancet Gastroenterology and Hepatology, 2022, 7, 332-341.	3.7	24
4	EoE CONNECT, the European Registry of Clinical, Environmental, and Genetic Determinants in Eosinophilic Esophagitis: rationale, design, and study protocol of a large-scale epidemiological study in Europe. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210742.	1.4	13
5	Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg). Clinical Gastroenterology and Hepatology, 2022, 20, 2243-2257.	2.4	15
6	Accurate and timely diagnosis of Eosinophilic Esophagitis improves over time in Europe. An analysis of the EoE CONNECT Registry. United European Gastroenterology Journal, 2022, 10, 507-517.	1.6	19
7	Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU. Journal of Clinical Medicine, 2022, 11, 3915.	1.0	2
8	Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry. Digestive Diseases and Sciences, 2021, 66, 2014-2023.	1.1	28
9	Severe sarcoidosis-like reaction in a patient with Crohn's Disease treated with infliximab. Any relationship?. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101696.	0.7	2
10	Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg). American Journal of Gastroenterology, 2021, 116, 1220-1229.	0.2	40
11	Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study. Alimentary Pharmacology and Therapeutics, 2021, 53, 1277-1288.	1.9	16
12	Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study. Journal of Clinical Medicine, 2021, 10, 2885.	1.0	38
13	Follow-Up Study Confirms the Presence of Gastric Cancer DNA Methylation Hallmarks in High-Risk Precursor Lesions. Cancers, 2021, 13, 2760.	1.7	4
14	The Role of Statins on Helicobacter pylori Eradication: Results from the European Registry on the Management of H. pylori (Hp-EuReg). Antibiotics, 2021, 10, 965.	1.5	6
15	European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain. Antibiotics, 2021, 10, 13.	1.5	12
16	Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry. Inflammatory Bowel Diseases, 2020, 26, 606-616.	0.9	29
17	Efficacy and safety of endoscopic balloon dilation in inflammatory bowel disease: results of the large multicenter study of the ENEIDA registry. Surgical Endoscopy and Other Interventional Techniques, 2020, 34, 1112-1122.	1.3	20
18	Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients. Clinical Gastroenterology and Hepatology, 2020, 18, 89-98.	2.4	62

#	ARTICLE	IF	CITATIONS
19	Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00218.	1.3	8
20	Bismuth quadruple regimen with tetracycline or doxycycline versus threeâ€inâ€one single capsule as thirdâ€line rescue therapy for <i>Helicobacter pylori</i> infection: Spanish data of the European <i>Helicobacter pylori</i> Registry (Hpâ€Reg). <i>Helicobacter</i> , 2020, 25, e12722.	1.6	17
21	Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 798-807.	1.9	72
22	<i>Helicobacter pylori</i> firstâ€line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on Hâ€pylori management (Hpâ€Reg). <i>Helicobacter</i> , 2020, 25, e12686.	1.6	27
23	Efficacy of Therapy for Eosinophilic Esophagitis in Real-World Practice. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2903-2911.e4.	2.4	51
24	Even non-experts identify non-dysplastic lesions in inflammatory bowel disease via chromoendoscopy: results of a screening program in real-life. <i>Endoscopy International Open</i> , 2019, 07, E743-E750.	0.9	8
25	Perioperative management and early complications after intestinal resection with ileocolonic anastomosis in Crohnâ€™s disease: analysis from the PRACTICROHN study. <i>Gastroenterology Report</i> , 2019, 7, 168-175.	0.6	16
26	Epidemiology: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481984703.	1.4	18
27	Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1492-1500.	0.6	37
28	Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results From the ENEIDA Registry. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1862-1870.	0.9	28
29	Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohnâ€™s patients: Results of the APPRECIATE trial. <i>Digestive and Liver Disease</i> , 2019, 51, 529-535.	0.4	3
30	Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients. <i>Digestive Diseases and Sciences</i> , 2019, 64, 846-854.	1.1	24
31	Screening for latent tuberculosis infection in patients with inflammatory bowel disease: Can interferon-gamma release assays replace the tuberculin skin test?. <i>Turkish Journal of Gastroenterology</i> , 2019, 29, 292-298.	0.4	5
32	Genetic variation analysis in a followâ€up study of gastric cancer precursor lesions confirms the association of <i>MUC2</i> variants with the evolution of the lesions and identifies a significant association with <i>NFKB1</i> and <i>CD14</i> . <i>International Journal of Cancer</i> , 2018, 143, 2777-2786.	2.3	9
33	Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1270-1279.	0.6	15
34	Adalimumab vs Azathioprine in the Prevention of Postoperative Crohnâ€™s Disease Recurrence. A GETECCU Randomised Trial. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1293-1301.	0.6	57
35	Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry. <i>American Journal of Gastroenterology</i> , 2017, 112, 1135-1143.	0.2	27
36	Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 792-800.	0.6	16

#	ARTICLE	IF	CITATIONS
37	Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. <i>American Journal of Gastroenterology</i> , 2017, 112, 120-131.	0.2	93
38	Accuracy of the Ultra-Rapid Urease Test for diagnosis of <i>Helicobacter pylori</i> infection. <i>Gastroenterology and Hepatology</i> , 2017, 40, 651-657.	0.2	15
39	Fourteen-day high-dose esomeprazole, amoxicillin and metronidazole as third-line treatment for <i>Helicobacter pylori</i> infection. <i>International Journal of Clinical Practice</i> , 2017, 71, e13004.	0.8	9
40	Molecular diagnosis of allergy to <i>Anisakis simplex</i> and <i>Gymnorhynchus gigas</i> fish parasites. <i>Allergologia Et Immunopathologia</i> , 2017, 45, 463-472.	1.0	7
41	Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients. <i>Journal of Gastroenterology</i> , 2017, 52, 788-799.	2.3	50
42	Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish follow-up multicenter study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 953-958.	1.4	87
43	Effectiveness of anti-TNF± drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNF± agent. <i>Digestive and Liver Disease</i> , 2016, 48, 613-619.	0.4	13
44	Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study). <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 186-195.	0.6	4
45	Resources Utilization and Costs the Year Before and After Starting Treatment with Adalimumab in Crohn's Disease Patients. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1631-1640.	0.9	8
46	Value of microarray allergen assay in the management of eosinophilic oesophagitis. <i>Allergologia Et Immunopathologia</i> , 2015, 43, 73-80.	1.0	12
47	Two-week, high-dose proton pump inhibitor, moxifloxacin triple <i>Helicobacter pylori</i> therapy after failure of standard triple or non-bismuth quadruple treatments. <i>Digestive and Liver Disease</i> , 2015, 47, 108-113.	0.4	22
48	Optimised empiric triple and concomitant therapy for <i>Helicobacter pylori</i> eradication in clinical practice: the OPRICON study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 581-589.	1.9	70
49	<i>Helicobacter Pylori</i> First-Line and Rescue Treatments in the Presence of Penicillin Allergy. <i>Digestive Diseases and Sciences</i> , 2015, 60, 458-464.	1.1	42
50	<i>Helicobacter pylori</i> second-line rescue therapy with levofloxacin and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 768-775.	1.9	91
51	Thiopurine Therapy Reduces the Incidence of Colorectal Neoplasia in Patients with Ulcerative Colitis. Data from the ENEIDA Registry. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 1063-1070.	0.6	45
52	Long-Term Loss of Response in Proton Pump Inhibitor-Responsive Esophageal Eosinophilia Is Uncommon and Influenced by CYP2C19 Genotype and Rhinoconjunctivitis. <i>American Journal of Gastroenterology</i> , 2015, 110, 1567-1575.	0.2	102
53	Accuracy of GastroPanel for the diagnosis of atrophic gastritis. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 941-948.	0.8	54
54	Third-Line Rescue Therapy with Bismuth-Containing Quadruple Regimen After Failure of Two Treatments (with Clarithromycin and Levofloxacin) for <i>H. pylori</i> Infection. <i>Digestive Diseases and Sciences</i> , 2014, 59, 383-389.	1.1	48

#	ARTICLE	IF	CITATIONS
55	Randomised clinical trial comparing sequential and concomitant therapies for <i>Helicobacter pylori</i> eradication in routine clinical practice. <i>Gut</i> , 2014, 63, 244-249.	6.1	119
56	Four-food group elimination diet for adult eosinophilic esophagitis: A prospective multicenter study. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 1093-1099.e1.	1.5	217
57	Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: Multicenter prospective observational study (REPENTINA 3). <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1529-1538.	0.6	45
58	Letter: the role of stent in the treatment of Crohn's disease strictures – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 503-504.	1.9	0
59	Diagnostic and therapeutic management of eosinophilic oesophagitis in children and adults: Results from a Spanish registry of clinical practice. <i>Digestive and Liver Disease</i> , 2013, 45, 562-568.	0.4	32
60	Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple – sequential or concomitant treatment to eradicate <i>H. pylori</i> infection. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 652-656.	0.6	32
61	Safety of Thiopurine Therapy in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1404-1410.	0.9	243
62	Second-line Therapy With Levofloxacin After Failure of Treatment to Eradicate <i>Helicobacter pylori</i> Infection. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 130-135.	1.1	60
63	Sigmoid perforation caused by a migrated biliary stent and closed with clips. <i>Endoscopy</i> , 2012, 44, E274-E274.	1.0	10
64	Endoscopic treatment with self-expanding metal stents for Crohn's disease strictures. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 833-839.	1.9	83
65	Long-term durability of response to adalimumab in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 685-690.	0.9	50
66	Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients. <i>World Journal of Gastroenterology</i> , 2012, 18, 4391.	1.4	78
67	Hemoperitoneum caused by hemorrhage of tubal vessels, a previously undescribed complication of colonoscopy. <i>Endoscopy</i> , 2011, 43, E93-E93.	1.0	0
68	Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. <i>Gut</i> , 2010, 59, 1340-1346.	6.1	168
69	Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: The RECLICU Study. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 629-636.	0.6	24
70	<i>Helicobacter pylori</i> first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin. <i>Digestive and Liver Disease</i> , 2010, 42, 287-290.	0.4	53
71	Prevalence and Factors Related to Hepatitis B and C in Inflammatory Bowel Disease Patients in Spain: A Nationwide, Multicenter Study. <i>American Journal of Gastroenterology</i> , 2009, 104, 57-63.	0.2	130